You’ve probably read the minoxidil side effects list on the carton, then read a forum thread that said something else entirely. Neither gave you a number. Here’s what the research reports, what it cannot yet tell you, and where the Canadian rules differ.
Key takeaways
- The most commonly reported effects of topical minoxidil are local to the scalp: itching, dryness, scaling, flaking, irritation and burning.
- A 2016 Cochrane review of female pattern hair loss recorded adverse events in 40 of 407 participants on twice-daily 2% topical minoxidil, against 28 of 320 on placebo.
- Much of the irritation blamed on minoxidil traces to propylene glycol in solutions, though allergy to minoxidil itself does occur.
- Topical minoxidil at 5% or less has been non-prescription in Canada since 21 August 2014, while oral tablets still require a prescription.
- In the largest low-dose oral minoxidil cohort of 1,404 patients, excess body hair led at 15.1%, with no life-threatening adverse effects observed.
What minoxidil is, and what it does not do
Minoxidil began as a blood pressure medication. Its sulphated metabolite opens potassium channels and relaxes vascular smooth muscle, which is how the oral form lowers blood pressure.
Whether that mechanism explains hair growth is less settled than most articles suggest. Messenger and Rundegren, in the British Journal of Dermatology in 2004, called potassium channel opening the leading explanation. They also noted no clear demonstration that those channels are expressed in the hair follicle.
One thing is not in doubt: minoxidil is not a DHT blocker. It is not a 5-alpha reductase inhibitor, and it does nothing to DHT. That is why the two are sometimes used alongside each other rather than as substitutes, as set out in how treatment options compare at different stages of hair loss.
Minoxidil side effects reported with topical use
MedlinePlus lists the common local effects as scalp itching, dryness, scaling, flaking, irritation and burning. Those turn up most often.
For frequency, the best citable figure comes from the 2016 Cochrane review by van Zuuren and colleagues. It covered 47 trials and 5,290 participants, 17 of them evaluating minoxidil. One caveat first: this review studied female pattern hair loss, so every participant was a woman. The local effects it measured are not sex-specific, but this is not a male-only figure. Among people using twice-daily 2% topical minoxidil, 40 of 407 reported an adverse event, against 28 of 320 on placebo. The relative risk was 1.24, with a 95% confidence interval of 0.82 to 1.87. That interval crosses 1, and the review graded the evidence low quality. The signal is real but imprecise.
On strength the evidence is mixed. Pooling four trials and 1,006 participants, the same review found no difference in adverse event counts between 2% and 5%, though those trials disagreed substantially. Individual trials point the other way. A 48-week trial of 393 men reported more itching and local irritation with 5%. A 2004 trial in 381 women found the same pattern plus more excess hair growth, and it sits inside that pooled figure rather than acting as a separate check on it. Both reported direction only, not a per-symptom rate.
The labelling adds two more. Stop and ask a doctor if unwanted facial hair growth occurs. Some people have also experienced changes in hair colour or texture. The American Academy of Dermatology advises applying to the scalp only, then washing the face.
Scalp irritation, dryness and the propylene glycol question
If your scalp burns and flakes, the drug may not be the problem. Propylene glycol, the solvent in solution formulations, is a well-documented culprit. A 2002 case series by Friedman and colleagues found it was the contactant in most patch-tested cases of allergic contact dermatitis, not the minoxidil.
That is not the whole picture. A 2025 systematic review in Acta Dermato-Venereologica pooled 21 studies. It identified 54 patients sensitized to minoxidil itself, against 12 sensitized to vehicle components. Allergy to the ingredient does happen.
Formulation matters. The 5% foam is propylene-glycol-free, while the 5% solution contains it. In a 24-week trial of 113 women, Blume-Peytavi and colleagues found 5% foam produced significantly lower rates of local intolerance than 2% solution, at P equal to 0.046. The difference was clearest in itching and dandruff.
One Canadian detail gets missed. Every 5% product currently in the Health Canada Drug Product Database is an aerosol foam. Canadian 2% products are solutions. If a page tells you to buy a 5% solution, it was written for a different market.
Shedding in the first weeks
An early increase in hair fall is expected. It is not evidence the treatment is failing. The American Academy of Dermatology puts the window plainly: for the first two to eight weeks, you may notice a temporary increase in hair loss.
The accepted explanation is that minoxidil shortens the resting phase of the hair cycle. Follicles enter a new growth phase early, and the old hairs are released. Messenger and Rundegren described this from animal studies and said it probably works similarly in humans. Treat it as the leading explanation, not a proven human mechanism.
Here is where most pages overreach. No verifiable incidence rate exists for shedding on topical minoxidil, so any percentage quoted is unsupported. A rate does exist for the oral form. In a 2024 chart review of 115 patients starting low-dose oral minoxidil, 6 patients, or 5.2%, experienced shedding. The authors called that lower than previously reported. The same paper describes what dermatologists see: shedding that begins two to four weeks in, lasts three to six weeks, and is usually self-limited.
Oral minoxidil in Canada and its systemic effects
Oral minoxidil is prescription-only in Canada, approved as an antihypertensive. Low-dose prescribing for hair is off-label, meaning outside the approved indication, and it requires clinical oversight.
The reference point is a 2021 multicentre retrospective study by Vañó-Galván and colleagues, covering 1,404 patients, 943 women and 461 men, mean age 43, ages 8 to 86.
| Reported effect | Rate in the 1,404-patient cohort |
|---|---|
| Excess body hair growth | 15.1% |
| Lightheadedness | 1.7% |
| Fluid retention | 1.3% |
| Rapid heartbeat | 0.9% |
| Headache | 0.4% |
| Swelling around the eyes | 0.3% |
| Insomnia | 0.2% |
Excess body hair led 14 patients, 0.5% of the cohort, to withdraw. Systemic effects caused discontinuation in 29 patients, or 1.2%. Total discontinuation for any adverse effect was 1.7%. The authors observed no life-threatening adverse effects. They also named their own limits: retrospective design, no control group.
The figure that circulates most widely needs context. Oral minoxidil carries a boxed warning for its blood pressure indication. It states that pericardial effusion, sometimes progressing to tamponade, has been seen in about 3% of treated patients not on dialysis. That figure comes from full antihypertensive doses, usually given with a beta blocker and a diuretic. The low-dose cohort of 1,404 recorded no life-threatening events. No large cohort has established a pericardial effusion rate for low-dose use. All three statements are true at once.
Topical and oral compared
| Topical minoxidil | Oral minoxidil | |
|---|---|---|
| Status in Canada | Non-prescription at 5% or less since 2014 | Prescription only, off-label for hair |
| Forms marketed in Canada | 5% aerosol foam, 2% solution | Tablet |
| Most reported effect | Local scalp irritation and itching | Excess body hair, 15.1% |
| Systemic effects | Uncommon, label lists stop-use triggers | Lightheadedness 1.7%, fluid retention 1.3% |
| Strongest evidence | 47-trial Cochrane review, 5,290 participants, all female | 1,404-patient cohort, no control group |
| Oversight | Available without a prescription | Requires a prescriber |
Neither column is the automatic answer. A prescriber weighs them.
What happens if you stop
The labelling is direct: continued use is necessary to increase and keep hair regrowth, or hair loss will begin again. MedlinePlus states that most new hair is lost within a few months after the drug is stopped. The label also notes that regrowth has not been shown to last longer than 48 weeks in large clinical trials with continuous treatment. That describes trial duration, not a cut-off for results.
Minoxidil and pets in the home
This gets under-reported, and it matters if you have a cat. A 2021 study in the Journal of the American Animal Hospital Association reviewed 211 exposure cases in dogs and cats, reported to a poison control centre from 2001 to 2019. Clinical signs developed in 87 animals, 62 cats and 25 dogs.
Among those that developed signs, illness was moderate or major in 56.0% of dogs and 59.7% of cats. Eight of the 62 cats that developed clinical signs died, 12.9% of that group. The most common route in cats was not the bottle, but contact while the owner applied the product, including licking their skin or pillowcase. Clinical signs occurred even after drops or licks.
So wash your hands after applying, let the scalp dry fully, and keep pets off your bedding.
Safety and who should speak with a healthcare provider first
The labelling lists circumstances in which topical minoxidil should not be used. Do not use it if:
- your hair loss is sudden or patchy
- you do not know the reason for your hair loss
- you have no family history of hair loss
- your scalp is red, inflamed, infected, irritated or painful
- you are under 18
- you are using other medicines on the scalp
Do not apply it to a sunburned or irritated scalp. Speak with a healthcare provider before starting if you have heart disease. The labelling states the product may be harmful if used when pregnant or breastfeeding, and the American Academy of Dermatology advises avoiding it in both.
Stop use and contact a healthcare provider if you experience chest pain, rapid heartbeat, faintness or dizziness, sudden unexplained weight gain, or swelling of the hands or feet. These are labelled stop-use triggers, not symptoms to monitor at home without advice.
If you are experiencing hair loss and are unsure which form applies, speak with a healthcare provider about whether treatment may be right for you.
Frequently asked questions
Is minoxidil safe?
No medication is without risk. Topical minoxidil has a well-characterized local effect profile and an imprecise frequency estimate. The 2016 Cochrane review found a relative risk of 1.24 for adverse events against placebo, on low-quality evidence, with a confidence interval crossing 1.
Does minoxidil cause more hair loss?
It can increase hair fall temporarily at the start. The American Academy of Dermatology describes a temporary increase during the first two to eight weeks. The accepted explanation is that resting follicles enter a new growth phase early, releasing old hairs. No reliable rate exists for topical shedding.
Does minoxidil have side effects everyone experiences?
No. Local scalp effects are reported most often, but they are not universal. In the 2016 Cochrane review, 40 of 407 participants on twice-daily 2% topical minoxidil reported an adverse event, against 28 of 320 on placebo. Most in both groups reported none.
Is oral minoxidil better than topical minoxidil?
Neither form is better in general terms. Topical minoxidil at 5% or less needs no prescription in Canada, and its effects are mostly local. The oral form is prescription-only and off-label for hair, with excess body hair reported in 15.1% of one cohort.
Is minoxidil toxic to dogs?
It is a real hazard to dogs and cats, and cats are affected more severely. In a 2021 review of 211 exposure cases, 87 animals developed clinical signs. Illness was moderate or major in 56.0% of dogs and 59.7% of cats. Drops or licks were enough.
Can you stop minoxidil once you start?
You can stop at any point, but the gains are not retained. The labelling states continued use is necessary to keep hair regrowth, and MedlinePlus notes that most new hair is lost within a few months of stopping. Speak with a provider first.
The bottom line
Most of what gets reported with topical minoxidil is local to the scalp, and the best frequency estimate is imprecise rather than reassuring. The oral form carries a broader effect profile, a prescription requirement in Canada, and one large retrospective cohort behind it.
Still weighing it up? Start with a realistic timeline for how long topical treatment takes to work, so you know what a normal first three months looks like. Then review the hair treatment options available through MyRocky, or read how an assessment with a licensed Canadian provider works if you’d rather have a clinician look first.
References
- van Zuuren EJ, Fedorowicz Z, Schoones J. Interventions for female pattern hair loss. Cochrane Database of Systematic Reviews, 2016, CD007628. https://pmc.ncbi.nlm.nih.gov/articles/PMC6457957/
- Vañó-Galván S, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. Journal of the American Academy of Dermatology, 2021;84(6):1644-1651. https://pubmed.ncbi.nlm.nih.gov/33639244/
- Health Canada. Prescription Drug List: Minoxidil. Government of Canada, effective 2014. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/minoxidil.html
- National Library of Medicine. Minoxidil Topical. MedlinePlus, 2023. https://medlineplus.gov/druginfo/meds/a689003.html
- Tater KC, Gwaltney-Brant S, Wismer T. Topical minoxidil exposures and toxicoses in dogs and cats: 211 cases (2001-2019). Journal of the American Animal Hospital Association, 2021;57(5):225-231. https://pubmed.ncbi.nlm.nih.gov/34370845/
Disclaimer: This article is intended for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider with any questions about a medical condition or treatment.
Editorial Standards: At Rocky Health, we’ve made it our mission to support men and women with trustworthy, easy-to-understand medical and health information online. Read more about our editorial standards here.












